Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta
"We believe our registrational ECLIPSE program will validate the potential of our combination of tobevibart and elebsiran to establish a new standard of care in both newly diagnosed and previously treated patients with chronic hepatitis delta.'
'People living with chronic hepatitis delta urgently need new options to treat their disease,' said Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, Vir Biotechnology. 'With the strong foundation of our previous data and the proven expertise of our team, we believe our registrational ECLIPSE program will validate the potential of our combination of tobevibart and elebsiran to establish a new standard of care in both newly diagnosed and previously treated patients with chronic hepatitis delta.'
'We are encouraged by the high rates of viral suppression demonstrated by the combination of tobevibart and elebsiran in our Phase 2 SOLSTICE study,' said Mark Eisner, M.D., M.P.H., Chief Medical Officer, Vir Biotechnology. 'Taken together, our ECLIPSE trials are designed to demonstrate the potential of our tobevibart and elebsiran combination therapy, including breadth of response and dosing convenience. These are key aspects for improving patients' quality of life and supporting long-term treatment adherence in real-world settings.'
CHD is an area of significant unmet medical need, with no approved treatments in the U.S. and limited options globally. CHD is the most severe form of chronic viral hepatitis, 1 with people living with the disease rapidly progressing to cirrhosis, liver failure 2 and liver-related death. 1 The objective of therapy is to eliminate the virus. Tobevibart in combination with elebsiran offers the potential to achieve this by tackling the viral lifecycle through multiple mechanisms.
The potential of the combination of tobevibart and elebsiran has been recognized by Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration (FDA), along with Priority Medicines (PRIME) and orphan drug status from the European Medicines Agency (EMA). These designations support the expedited development of treatments for serious diseases where there is a significant unmet medical need.
About the ECLIPSE Registrational Program
ECLIPSE is a registrational program to evaluate the safety and efficacy of tobevibart in combination with elebsiran in patients with chronic hepatitis delta (CHD). ECLIPSE includes three randomized, controlled trials designed to evaluate the combination therapy in comparison to deferred treatment or bulevirtide. ECLIPSE 1 (NCT06903338) is a Phase 3 trial evaluating the safety and efficacy of tobevibart in combination with elebsiran compared to deferred treatment in the U.S. or other regions where bulevirtide use is limited. ECLIPSE 2 is a Phase 3 trial that will evaluate the efficacy and safety of switching to tobevibart and elebsiran in people with CHD who have not achieved viral suppression with bulevirtide therapy. ECLIPSE 1 and 2 are designed to provide the registrational efficacy and safety data needed for potential submission to global regulatory agencies, and both trials are currently recruiting. ECLIPSE 3 is a Phase 2b head-to-head trial to evaluate tobevibart and elebsiran compared with bulevirtide in bulevirtide-naïve patients, and it is designed to provide important supportive data to help establish access and reimbursement in key markets.
ECLIPSE 3 plans to enroll participants who have never received bulevirtide for the treatment of CHD. Participants will be randomized 2:1 to receive the combination of tobevibart and elebsiran or bulevirtide. The primary endpoint in ECLIPSE 3 measures hepatitis delta virus (HDV) RNA at the lower limit of quantification target not detected, HDV RNA TND (defined as HDV RNA = 0 IU/mL), at Week 48.
About Tobevibart and Elebsiran
Tobevibart is an investigational broadly neutralizing monoclonal antibody targeting the hepatitis B surface antigen (HBsAg). It is designed to inhibit the entry of hepatitis B and hepatitis delta viruses into hepatocytes and to reduce the level of circulating viral and subviral particles in the blood. Tobevibart was identified using Vir Biotechnology's proprietary monoclonal antibody discovery platform. The Fc domain has been engineered to increase immune engagement and clearance of HBsAg immune complexes and incorporates Xencor's Xtend™ technology to extend half-life. Tobevibart is administered subcutaneously, and it is currently in clinical development for the treatment of patients with chronic hepatitis delta.
Elebsiran is an investigational hepatitis B virus-targeting small interfering ribonucleic acid (siRNA) discovered by Alnylam Pharmaceuticals, Inc. It is designed to degrade hepatitis B virus RNA transcripts and limit the production of hepatitis B surface antigen. Current data indicate that it has the potential to have direct antiviral activity against hepatitis B virus and hepatitis delta virus. Elebsiran is administered subcutaneously, and it is currently in clinical development for the treatment of patients with chronic hepatitis delta.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.
References:
1 WHO Hepatitis Delta Factsheet – Hepatitis D (who.int), accessed July 2025
2 CDC What is Hepatitis D - FAQ | CDC, accessed July 2025
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'should,' 'could,' 'may,' 'might,' 'will,' 'plan,' 'potential,' 'aim,' 'expect,' 'anticipate,' 'promising' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements regarding: the therapeutic potential of the combination of tobevibart and elebsiran to treat CHD and Vir Biotechnology's belief that it can establish a new standard of care in both newly diagnosed and previously treated patients with CHD; Vir Biotechnology's clinical development plans and expectations for the ECLIPSE Phase 3 registrational program, including protocols for and enrollment into ongoing and planned clinical studies, target endpoints and data readouts; Vir Biotechnology's strategy and plans; and any assumptions underlying any of the foregoing. Many factors may cause differences between current expectations and actual results, including, without limitation: unexpected safety or efficacy data or results observed during clinical studies or in data readouts, including the occurrence of adverse safety events; risks of unexpected costs, delays or other unexpected hurdles; challenges in accessing manufacturing capacity; clinical site activation rates or clinical enrollment rates that are lower than expected; the timing and outcome of Vir Biotechnology's planned interactions with regulatory authorities, as well as general difficulties in obtaining any necessary regulatory approvals; successful development and/or commercialization of alternative product candidates by Vir Biotechnology's competitors, as well as changes in expected or existing competition; geopolitical changes or other external factors; and unexpected litigation or other disputes. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. The actual results may vary from the anticipated results, and the variations may be material. You are cautioned not to place undue reliance on any scientific data presented or these forward-looking statements, which are based on Vir Biotechnology's available information, expectations and assumptions as of the date of this press release. Other factors that may cause Vir Biotechnology's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Vir Biotechnology's filings with the U.S. Securities and Exchange Commission, including the section titled 'Risk Factors' contained therein. Except as required by law, Vir Biotechnology assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Why Is Sotera Health Company (SHC) Stock Soaring Today
What Happened? Shares of healthcare services company Sotera Health (NASDAQ:) jumped 20% in the morning session after the company reported strong second-quarter 2025 results that surpassed analyst expectations and raised its full-year financial outlook. The healthcare sterilization and lab testing provider announced second-quarter adjusted earnings per share of $0.20, beating analyst estimates of $0.17. Revenue for the quarter came in at $294.3 million, a 6.4% year-over-year increase, which also surpassed the consensus estimate of $275.6 million. The company's profitability also improved, with adjusted EBITDA (a measure of operational profitability) of $150.7 million, beating analyst forecasts by 9.8%. Following the strong performance, Sotera Health raised its full-year 2025 guidance, increasing its forecast for adjusted earnings per share by 7.5% to $0.78 at the midpoint. Is now the time to buy Sotera Health Company? Access our full analysis report here, it's free. What Is The Market Telling Us Sotera Health Company's shares are somewhat volatile and have had 10 moves greater than 5% over the last year. But moves this big are rare even for Sotera Health Company and indicate this news significantly impacted the market's perception of the business. The previous big move we wrote about was 18 days ago when the stock gained 3.4% amid broader positive market sentiment ahead of a busy week for corporate earnings. U.S. stock futures indicated a higher open for the markets, setting a positive tone for investors who were anticipating a heavy slate of earnings reports from major companies during the week. Notably, the earnings season got off to a strong start: More than 85% of the S&P 500 stocks that reported earnings exceeded expectations, according to FactSet data. This robust performance fueled positive sentiment, suggesting that corporate profitability remained resilient despite ongoing economic uncertainties. Sotera Health Company is down 1.4% since the beginning of the year, and at $13.43 per share, it is trading 20.6% below its 52-week high of $16.91 from September 2024. Investors who bought $1,000 worth of Sotera Health Company's shares at the IPO in November 2020 would now be looking at an investment worth $534.90. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
Yahoo
6 minutes ago
- Yahoo
Is Super Micro Computer Stock Headed for $15 or $70 After Giant Post-Earnings Plunge?
After putting accounting controversies and Nasdaq delisting fears stemming from the delayed filings in the rearview mirror, Super Micro Computer (SMCI) had been on a strong recovery run this year. SMCI stock once again regained traction as investors bet big on its leadership in the artificial intelligence (AI) hardware space, growing demand for next-gen servers, and close partnership with chip giant Nvidia (NVDA) — all of which painted a promising growth story. But the narrative took a sharp turn in the wrong direction after the company dropped its fourth-quarter earnings report on Aug. 5. Shares of SMCI sank more than 18% in the following trading session, as Super Micro missed Wall Street's expectations on both revenue and earnings. Even guidance fell short, sparking fresh concerns about slowing growth and rising competition. More News from Barchart Robinhood Stock Seemingly Can't Be Stopped in 2025. Is It Too Late to Buy HOOD Here? Dear Ford Stock Fans, Mark Your Calendar for August 11 Cathie Wood Is Buying Shares of This Little-Known Ethereum Treasury Company. Should You? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Investor sentiment around SMCI stock has clearly taken a hit, and analysts' opinions are now deeply divided. On one end, the most bullish target on Wall Street suggests that SMCI stock could soar to $70, while on the other side, the most bearish sees it dropping all the way to $15 per share. So, with expectations stretched so far apart, can SMCI defy the doubts and reclaim its momentum? Or is there more downside still to come? About Super Micro Stock Super Micro Computer specializes in building high-powered, energy-efficient servers to support surging demand from AI, cloud services, and data centers. With operations across the U.S., Taiwan, and the Netherlands, the company has built a solid international footprint and currently holds a market capitalization of $27.8 billion. After sliding last year under the weight of negative headlines, SMCI stock came roaring back in 2025, hitting a fresh high of $66.44 in February. Even after pulling back some 32% from that peak, the stock remains up an impressive 50% so far this year, well ahead of the broader S&P 500 Index's ($SPX) modest 8.5% gain year-to-date (YTD). However, the comeback rally appears to be facing turbulence lately. SMCI is once again under pressure following its latest earnings miss, with shares tumbling 19% in just the past five trading days. A Look Inside Super Micro's Q4 Earnings Super Micro's fiscal 2025 fourth-quarter earnings report released earlier this month came as a letdown to investors, missing Wall Street's expectations on both the top and bottom lines. Revenue for the quarter rose 7.4% year-over-year (YOY) to $5.8 billion but still fell short of the $5.9 billion analysts had expected. Adjusted EPS came in at $0.41, marking a notable 24% decline from the prior year and falling below the consensus estimate of $0.44, partly because of the impact from President Donald Trump's tariffs on goods imported into the United States. While the company pointed to tariffs as a key reason for the earnings shortfall, the miss stung even more given the backdrop of soaring demand for AI infrastructure, which had set investors' expectations sky high. Instead of a blowout quarter, the results revealed mounting cost pressures and thinner margins, casting doubt on Super Micro's ability to deliver strong profits even as sales continue to rise. A key red flag was the drop in gross margin, which slipped to 9.5% from 10.2% a year ago. The decline suggests the company may be facing pricing pressure or higher costs, likely tied to competitive dynamics or more expensive AI components. As of June 30, Super Micro reported $5.2 billion in cash and equivalents, alongside $4.8 billion in total bank debt and convertible notes. Unfortunately, the disappointment didn't end at Super Micro's Q4 financials. The company's guidance for Q1 of fiscal 2026 also fell short of expectations. Management expects revenue to land between $6 billion and $7 billion, while adjusted EPS is expected to be between $0.40 and $0.52. Both of these figures miss Wall Street's forecasts for $6.6 billion in revenue and $0.59 in EPS. Over the longer term, analysts tracking Super Micro project the company's bottom line to rise 19.2% YOY to $2.05 per share in fiscal 2026, then leap 21% annually to $2.49 in fiscal 2027. What Do Analysts Think About Super Micro Stock? After the disappointing Q4 showing, several Wall Street analysts struck a more cautious tone. For instance, JPMorgan analyst Samik Chatterjee lowered the firm's price target to $45 from $46, maintaining a 'Neutral' rating. Chatterjee pointed to capital constraints and customer hesitation as key reasons the company fell short of expectations. On the other hand, Bank of America Securities analyst Ruplu Bhattacharya slightly raised the price target to $37 from $35 while sticking with an 'Underperform' rating. The analyst noted that gross margins were pressured once again, this time due to inventory reserves for older products. Bhattacharya explained that many customers are opting to wait for Nvidia's upcoming B300/GB300 GPUs, which has weighed on current demand. Overall, Wall Street sentiment on Super Micro is tilting cautious, with SMCI stock earning a consensus rating of 'Hold.' Among the 16 analysts covering the stock, opinions are clearly mixed. Only four recommend a 'Strong Buy,' while three lean toward a 'Moderate Buy.' The majority of analysts take a wait-and-see approach, with six suggesting 'Hold.' On the bearish side, one analyst has a 'Moderate Sell' rating for SMCI and two assign a 'Strong Sell' rating, reflecting growing uncertainty around the company's near-term outlook. SMCI stock has a Street-high price target of $70, indicating nearly 54% potential upside. The lowest target of $15 suggests a steep 67% drop from current levels. Key Takeaways Super Micro's wide price target range, spanning from $15 to a Street-high of $70, underscores the uncertainty surrounding its near-term trajectory. While some analysts remain bullish on its long-term AI-driven potential, others are wary of execution risks and margin pressures. With sentiment this divided, the stock's path forward may remain volatile as investors wait for more apparent signs of sustained growth. On the date of publication, Anushka Mukherji did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
6 minutes ago
- Yahoo
Why Sezzle Stock Plunged Today
Key Points Sezzle delivered another round of strong growth on the top and bottom lines. Guidance calls for growth to decelerate in the second half of the year. The stock looks well priced based on its forward P/E. 10 stocks we like better than Sezzle › Shares of Sezzle (NASDAQ: SEZL) were taking a dive after better-than-expected results on the top and bottom lines were not enough to please investors. As a result, the stock was down 33.7% on the news as of 11:42 a.m. ET. Sezzle cools off Sezzle, a buy now, pay later (BNPL) company that's taken the market by storm over the last two years, continued to deliver impressive growth. Revenue grew 76.4% to $98.7 million, which beat analyst estimates at $94.9 million. Sezzle's monthly on-demand and subscribers metric reached 748,000, up from 658,000 in the previous quarter, showing solid growth in its high-frequency user base. Gross merchandise volume was also strong, up 74.2% to $927 million. Margins continued to expand as operating income jumped 116.1% to $36.1 million, and adjusted earnings per share was up 97% to $0.69. CEO Charlie Youakim said, "The product features and marketing initiative we've rolled out are driving stronger engagement and broader adoption." What's next for Sezzle While its results were strong, given its blistering growth coming into the report, investors may have expected a wider beat. Additionally, Sezzle's guidance calls for its growth to continue to decelerate as the company sees revenue growth of 60%-65% and adjusted earnings per share of $3.25, which was just slightly below the consensus at $3.26. After soaring growth through the first half of the year, that reflects a significant moderation in the second half of the year as well. Still, the stock now trades at a forward P/E of under 30, which looks like a great price for the fast-growing, disruptive BNPL player. Should you invest $1,000 in Sezzle right now? Before you buy stock in Sezzle, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Sezzle wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!* Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Jeremy Bowman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Sezzle. The Motley Fool has a disclosure policy. Why Sezzle Stock Plunged Today was originally published by The Motley Fool Sign in to access your portfolio
